Aarti Drugs share news, announcements and annual reports
NSE: AARTIDRUGSBSE: 524348Pharmaceuticals & BiotechnologySmall Cap
Aarti Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1993 on BSE, Sep 2003 on NSE
Last close ₹449.00up ₹1.10 (0.25%)BSE ₹448.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹447.90.
29 Oct: open ₹440.00, high ₹457.95, low ₹434.25
52-week range of traded prices to 29 Oct 2026
₹318.95Low, 30 Mar 2026₹534.00High, 10 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,098 Cr930th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.44
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.65
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.45%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.37
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,51,96822.6% delivered
Aarti Drugs board and management
37 filed, newest first.
Sep 2026
30 Sep · Management
30 Sep · Management
26 Sep · Management
Sep 2025
24 Sep · Management
Sep 2024
20 Sep · Management
Jul 2024
26 Jul · Management
Mar 2024
29 Mar · Management
Apr 2023
29 Apr · Management
May 2022
Oct 2021
Apr 2019
Mar 2019
May 2018
16 May · Management
May 2017
Jun 2016
22 Jun · Management
Feb 2016
Dec 2015
Sep 2014
26 Sep · Management
Following changes have been effected /approved at the meeting of the Board of Directors held on September 26, 2014: 1. CA Priti P. Savla, has been appointed as an Independent and Women Director of the Company to fill the casual vacancy caused by resignation of CS Sunil M. Dedhia on April 01, 2014. 2. Shri Rashesh C. Gogri, Whole-time Direclor has been appointed and re-designated as the Managing Director of the Company.26 Sep · Management
Following changes have been effected /approved at the meeting of the Board of Directors held on September 26, 2014:
Apr 2014
7 Apr · Management
Jul 2012
26 Jul · Management
Mr. Harshit M. SavIa, Jt. Managing Director of the Company has resigned from the position of Chief Financial Officer (CFO) with effect from July 06, 2012. Further, the Company has informed that Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company with effect from July 06, 2012.
Mar 2011
9 Mar · Management
Aarti Drugs Limited. has informed the Exchange that Mr. Harshit M. Savla, Jt. Managing Director of the Company has resigned from the position of Compliance Officer with effect from February 21, 2011. Company has further informed that Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company with effect from February 21, 2011
Aug 2010
12 Aug · Management
Mr. Sudhirpraksh B. Sawant, Independent Director of the Company has resigned from the office of the Director of the Company with effect from July 30 2010. The registration has been duly accepted by the Board at its Meeting held on July 30,2010.
Jul 2009
30 Jul · Management
Aarti Drugs Ltd. has submitted to the Exchange the Auditor's Report in respect of the Audited Financial Results for the quarter ended June 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
25 May · Management
Aarti Drugs Ltd. has submitted to the Exchange the Auditor's Report in respect of the Audited Financial Results for the quarter and year ended March 31, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 May · Management
Aarti Drugs Ltd. has informed the Exchange that Shri Dilip Maharana has been appointed as Company Secretary and Compliance Officer of the Company w.e.f. March 02, 2009.15 May · Management
Aarti Drugs Ltd. has informed the Exchange vide its letter dated May 15, 2009 that "The Board of Directors of the Company at its meeting held on October 20, 2008 has duly appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company to comply with the amended clause 49 IA of the Listing Agreement vide SEBI circular no. SEBI/CFD/DIL/CG/1/2008/08/04."
Jan 2009
30 Jan · Management
Aarti Drugs Ltd. has submitted to the Exchange the auditor's report in respect of the audited financial results for the quarter ended December 31,2008.A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
31 Mar · Management
Aarti Drugs Ltd. has informed the Exchange that : "Mr. Nilesh N. Pingale, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from 31st March, 2008".
Jan 2008
28 Jan · Management
Aarti Drugs Ltd. has submitted to the Exchange the auditor's report in respect of the quarterly financial results for the quarter ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
17 Aug · Management
Aarti Drugs Ltd. had informed the Exchange that : "Mr. Satish P. Nachane, Managing Director of the Company has resigned from the office of the Managing Director of the Company with effect from 30th July, 2007. The Resignation has been duly accepted by Board at its Meeting held on 30th July, 2007". Now the Company has clarified the Exchange that "Mr. Satish P Nachane, Managing Director of the Company has also resigned as a Director of the Company with effect from 30th July, 2007. The resignation has been duly accepted by the Board at its Meeting held on 30th July, 2007".1 Aug · Management
Aarti Drugs Ltd. has informed the Exchange that : "Mr. Satish P. Nachane, Managing Director of the Company has resigned from the office of the Managing Director of the Company with effect from 30th July, 2007. The Resignation has been duly accepted by Board at its Meeting held on 30th July, 2007".1 Aug · Management
Aarti Drugs Ltd. has informed the Exchange that : " Upon expiration of the previous tenures, the following Directors of the Company have been reappointed for a tenure of five years each w.e.f. 1st June, 2007 vide Board Resolution dated 18th May, 2007: 1) Prakash M. Patil :- Managing Director. 2) Satish P. Nachane :- Managing Director. 3) Harshit M. Savla :- Joint Managing Director. 4) Harit P. Shah :- Wholetime Director.